Edward Khantzian

Last updated

Edward Khantzian was a professor of psychiatry at Harvard Medical School. [1] Beginning in the 1970s, [2] he developed a progressively more coherent and empirically-grounded self-medication hypothesis of drug abuse, [3] [4] which states that individuals use drugs in an attempt to self-medicate states of distress and suffering. [5]

Dr. Khantzian is a first generation Armenian-American born in Haverhill Massachusetts. His parents were born in Turkey, his father immigrated to the United States in 1912. Khantzian's mother survived the Armenian genocide that started in 1915, moving to the U.S. in the late 1920s. Edward Khantzian was born in 1935 and grew up in Haverhill, a shoe town, where both parents worked in the then flourishing shoe industry.

Educated in local school systems, he began his university studies in the Evening Divisions of Merrimack College and Boston University, graduating from the latter in 1958. After working as a technical writer for Raytheon for one year, he commenced his medical training at Albany Medical College in 1959, and graduated in 1963. He completed an internship at Rhode Island Hospital in Providence, Rhode Island. Subsequently, he commenced his training in psychiatry at the Massachusetts Mental Health Mental Center, a Harvard Medical School-affiliated facility. He joined the staff and Harvard teaching faculty at Cambridge Hospital, where he worked for most of his career. He completed psychoanalytic training at the Boston Psychoanalytic Society and Institute in 1973.

Starting early in his career he became involved in multiple clinical and investigative studies of addiction, with an emphasis on pursuing a psychodynamic understanding of the psychological vulnerabilities that predispose to addictive disorders. [6] Considered a pioneer in addiction studies, he gained recognition for his development of the self-medication hypothesis. He also developed modified psychodynamic individual and group treatments for alcohol and other drug dependent individuals, [7] as well as exploring ingredients that seem to make 12-step programs effective.

Khantzian is a founding member and past president of the American Academy of Addiction Psychiatry. In 2016, the Massachusetts Psychiatric Society awarded Khantzian with their Lifetime Achievement Award. [8]

Related Research Articles

<span class="mw-page-title-main">Kleptomania</span> Inability to resist the urge to steal

Kleptomania is the inability to resist the urge to steal items, usually for reasons other than personal use or financial gain. First described in 1816, kleptomania is classified in psychiatry as an impulse control disorder. Some of the main characteristics of the disorder suggest that kleptomania could be an obsessive-compulsive spectrum disorder, but also share similarities with addictive and mood disorders.

Self-medication, sometime called do-it-yourself (DIY) medicine, is a human behavior in which an individual uses a substance or any exogenous influence to self-administer treatment for physical or psychological conditions, for example headaches or fatigue.

Psychodynamic psychotherapy and psychoanalytic psychotherapy are two categories of psychological therapies. Their main purpose is revealing the unconscious content of a client's psyche in an effort to alleviate psychic tension, which is inner conflict within the mind that was created in a situation of extreme stress or emotional hardship, often in the state of distress. The terms "psychoanalytic psychotherapy" and "psychodynamic psychotherapy" are often used interchangeably, but a distinction can be made in practice: though psychodynamic psychotherapy largely relies on psychoanalytical theory, it employs substantially shorter treatment periods than traditional psychoanalytical therapies. Psychodynamic psychotherapy is evidence-based; the effectiveness of psychoanalysis and its relationship to facts is disputed.

Biological psychiatry or biopsychiatry is an approach to psychiatry that aims to understand mental disorder in terms of the biological function of the nervous system. It is interdisciplinary in its approach and draws on sciences such as neuroscience, psychopharmacology, biochemistry, genetics, epigenetics and physiology to investigate the biological bases of behavior and psychopathology. Biopsychiatry is the branch of medicine which deals with the study of the biological function of the nervous system in mental disorders.

Dr. Robert Glick is a professor of psychiatry at Columbia University College of Physicians and Surgeons, and a Supervising and Training Psychoanalyst at the Columbia University Center for Psychoanalytic Training and Research; he was formerly a director of the Center.

Interpersonal psychotherapy (IPT) is a brief, attachment-focused psychotherapy that centers on resolving interpersonal problems and symptomatic recovery. It is an empirically supported treatment (EST) that follows a highly structured and time-limited approach and is intended to be completed within 12–16 weeks. IPT is based on the principle that relationships and life events impact mood and that the reverse is also true. It was developed by Gerald Klerman and Myrna Weissman for major depression in the 1970s and has since been adapted for other mental disorders. IPT is an empirically validated intervention for depressive disorders, and is more effective when used in combination with psychiatric medications. Along with cognitive behavioral therapy (CBT), IPT is recommended in treatment guidelines as a psychosocial treatment of choice for depression.

Mentalization-based treatment (MBT) is an integrative form of psychotherapy, bringing together aspects of psychodynamic, cognitive-behavioral, systemic and ecological approaches. MBT was developed and manualised by Peter Fonagy and Anthony Bateman, designed for individuals with borderline personality disorder (BPD). Some of these individuals suffer from disorganized attachment and failed to develop a robust mentalization capacity. Fonagy and Bateman define mentalization as the process by which we implicitly and explicitly interpret the actions of oneself and others as meaningful on the basis of intentional mental states. The object of treatment is that patients with BPD increase their mentalization capacity, which should improve affect regulation, thereby reducing suicidality and self-harm, as well as strengthening interpersonal relationships.

<span class="mw-page-title-main">Peter Fonagy</span> British psychoanalyst & psychologist

Peter Fonagy, is a Hungarian-born British psychoanalyst and clinical psychologist. He studied clinical psychology at University College London. He is a Professor of Contemporary Psychoanalysis and Developmental Science Head of the Division of Psychology and Language Sciences at University College London, Chief Executive of the Anna Freud Centre, and a training and supervising analyst in the British Psycho-Analytical Society in child and adult analysis. His clinical interests center on issues of borderline psychopathology, violence, and early attachment relationships. His work attempts to integrate empirical research with psychoanalytic theory. He has published over 500 papers, and 270 chapters and has authored 19 and edited 17 books.

Jeffrey H. Meyer is a scientist and professor working with mood and anxiety disorders using neuroimaging at the Department of Psychiatry, University of Toronto. He is currently the head of the Neurochemical Imaging Program in Mood and Anxiety Disorders in the Brain Health Imaging Centre at the Campbell Family Mental Health Research Institute and is working as a Senior Scientist in the General and Health Systems Psychiatry Division at the Centre for Addiction and Mental Health. He has also been awarded with the Tier 1 Canada Research Chair in the Neurochemistry of Major Depression.

The mainstay of management of borderline personality disorder is various forms of psychotherapy with medications being found to be of little use.

Dr. Allan Abbass is professor, psychiatrist, and founding Director of the Centre for Emotions and Health at Dalhousie University in Halifax, Nova Scotia, Canada.

Daniel A. Geller is an Australian American pediatrician and psychiatrist who specializes in the treatment of pediatric obsessive–compulsive disorder (OCD). Geller is triple board certified in Pediatrics, Psychiatry, and Child & Adolescent Psychiatry, and is director of the Pediatric OCD Program at Massachusetts General Hospital.

<span class="mw-page-title-main">Andrew J. Gerber</span>

Andrew J. Gerber is an American psychoanalyst and the current president and medical director of Silver Hill Hospital in New Canaan, Connecticut. His principal interests and research lie in studying the neurobiological bases of social cognition, particularly in relation to autism spectrum disorders and change in response to psychotherapy. He is a member of the American Academy of Child and Adolescent Psychiatry, American Psychiatric Association, American Psychoanalytic Association and the Psychoanalytic Psychodynamic Research Society.

<span class="mw-page-title-main">Eric Plakun</span> American researcher and forensic psychiatrist

Eric M. Plakun is an American psychiatrist, psychoanalyst, researcher and forensic psychiatrist. He is the current medical director/CEO at the Austen Riggs Center in Stockbridge, Massachusetts. Plakun's primary interests include the mental health advocacy, full implementation of the mental health parity law, access-to-care issues, and reducing health disparities; the value of and evidence base for psychosocial treatments and the diagnosis, treatment, longitudinal course and outcome of patients with borderline personality disorder and treatment resistant disorders. Plakun has been widely published and quoted in the media on psychotherapy and psychiatry, including in The New York Times and The Globe and Mail. He has appeared in the media to discuss his psychiatric work on WAMC, the Albany, New York, affiliate of NPR. and on CBS 60 Minutes. His psychiatric research has been widely cited.

Hilary Patricia Blumberg is a medical doctor and the inaugural John and Hope Furth Professor of Psychiatry at the Yale School of Medicine. She is also a professor of Radiology and Biomedical Imaging, and works in the Child Study Center at Yale where she has been a faculty member since 1998. She attended Harvard University as an undergraduate, and completed medical school at Cornell University Medical College (1990). She completed her medical internship and psychiatry residency at Cornell University Medical College/New York Hospital, and her neuroimaging fellowship training at Cornell University, Weill Medical College. She has received the 2006 National Alliance for Research in Schizophrenia and Depression (NARSAD) and the Gerald L. Klerman Award for Clinical Research. Blumberg has authored a number of scientific articles that focus on bipolar disorder, neuroimaging, and effects of specific genetic variations, developmental trajectories and structure-function relationships.

Lance M. Dodes is an American psychiatrist and psychoanalyst best known for his theory that all addictions are psychological compulsions.

<span class="mw-page-title-main">Jan Fawcett</span> American psychiatrist, educator and author

Jan A. Fawcett was an American psychiatrist, educator, and author. His research career focused on the mechanism of action of antidepressant medications and the development of more effective medications for severe depression and treatment modifiable factors leading up to suicide. Fawcett died on May 9, 2022, after a long health struggle.

<span class="mw-page-title-main">Edward Ross Ritvo</span> American psychiatrist, autism researcher (1930–2020)

Edward Ross Ritvo was an American psychiatrist known for his research on genetic components of autism. He was a professor emeritus of UCLA's Neuropsychiatric Institute.

Mauricio Tohen is a Mexican American research psychiatrist, Distinguished Professor, and Chairman of the Department of Psychiatry & Behavioral Sciences at the University of New Mexico. Tohen's research has focused on the epidemiology, outcome, and treatment of bipolar and psychotic disorders, and is especially known for innovating the design of clinical trials and the criteria to determine outcome in such diseases. Tohen has edited several books on his specialties. His social awareness has been noted in the promotion of programs to improve mental health care in areas such as substance abuse, bipolar disorder and schizophrenia.

Irvin M. Cohen, M.D. (1922–2019) was a psychiatrist specializing in psychopharmacology, recognized for his role in the early use of chlorpromazine in the treatment of schizophrenia, the development of the first benzodiazepine (Librium) treatments in depressive patients, and in the adoption of lithium to treat bipolar disorder.

References

  1. ↑ "Harvard Catalyst Profiles: Edward John Khantzian, M.D." Harvard University. Archived from the original on January 2, 2015. Retrieved January 1, 2015.
  2. ↑ Khantzian, Edward J.; Mack, John E.; Schatzberg, Alan F. (1974). "Heroin Use as an Attempt To Cope: Clinical Observations". American Journal of Psychiatry. 131 (2): 160–164. doi:10.1176/ajp.131.2.160. ISSN   0002-953X. PMID   4809043.
  3. ↑ Khantzian, E. J. (1985). "The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence". American Journal of Psychiatry. 142 (11): 1259–1264. doi:10.1176/ajp.142.11.1259. ISSN   0002-953X. PMID   3904487.
  4. ↑ Khantzian, Edward J. (1997). "The Self-Medication Hypothesis of Substance Use Disorders: A Reconsideration and Recent Applications". Harvard Review of Psychiatry. 4 (5): 231–244. doi:10.3109/10673229709030550. ISSN   1067-3229. PMID   9385000. S2CID   39531697.
  5. ↑ Fetting, Margaret (2012). Perspectives on Addiction: An Integrative Treatment Model with Clinical Case Studies (PDF). Thousand Oaks, California: SAGE. pp. 93–110. ISBN   9781412990998 . Retrieved January 1, 2015.
  6. ↑ Khantzian, E. J. (1987). "A Clinical Perspective of the Cause–Consequence Controversy in Alcoholic and Addictive Suffering". Journal of the American Academy of Psychoanalysis. 15 (4): 521–537. doi:10.1521/jaap.1.1987.15.4.521. ISSN   0090-3604. PMID   3312132.
  7. ↑ Khantzian, Edward J. (2001). "Reflections on Group Treatments as Corrective Experiences for Addictive Vulnerability". International Journal of Group Psychotherapy. 51 (1): 11–20. doi:10.1521/ijgp.51.1.11.49729. ISSN   0020-7284. PMID   11191591. S2CID   46572660.
  8. ↑ "Awards & Recognition - Edward Khantzian, MD: Lifetime Achievement Award". Cambridge Health Alliance. Retrieved 2020-07-27.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.